Related Blog Posts

Switzerland, Molecular Partners Secures CHF46M in Series B Financing

2 hours ago ago from FinSMEs

Molecular Partners AG, a Zurich, Switzerland-based developer of protein therapeutics, has announced the closing of its CHF 46 million (€30m, $45m) Series B equity investment round. The round was led by new investor Essex Woodlands Health Ventures, a venture capital and growth equity firm in the healthcare industry, with participation from all existing investors including Index Ventures, Johnson & Johnson Development Corporation, BB ...

Related News

Nothing to see... move along.

Related Videos

Nothing to see... move along.